Nodenza Venture Partners to attend the LSX World Congress USA 2025 in Boston
- Article
- Sep 10, 2025
- 1 Min Read
Written By Nodenza
Boston, MA – September 15-17, 2025 – Nodenza Venture Partners (“Nodenza”) will participate in the LSX World Congress USA.
The firm will engage with senior executives, venture investors, and strategic partners across biotechnology, medtech, and health technology sectors.
Nodenza’s investment strategy targets clinical proof-of-concept (IND through Phase 2) alongside product launch assets advancing toward commercialization.
Event Information: LSX World Congress USA
Contacts
Nodenza Venture Partner
Notes For Editors
About Nodenza Venture Partners
Nodenza Venture Partners provides investment and operational support to clinical proof-of-concept and product launch biotech and medtech companies seeking to bring exceptional benefits to patients. Our bi-modal investment strategy combines early-stage opportunities – advancing new treatment modalities through active IND to phase 2 – with commercial targets supporting their transition from scientific to commercial companies delivering strong upside potential. Established by a team of experienced life sciences entrepreneurs, founders and leaders, our approach leverages Nodenza’s extensive expertise in the creation and growth of new companies, as well as late-stage product development and launch.
